From cancer survivor to clinical trial innovator

How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.

By Kelly Bilodeau • May 3, 2022

One company's failed drug is this company's 'jewel'

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

By Meagan Parrish • May 2, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

A nuclear threat spurs France's Medesis to advance radiation therapy

In the event of a nuclear event — intentional or accidental — rapid and widespread deployment of effective treatments is paramount.

By Kelly Bilodeau • May 2, 2022

How an open platform can shake up the drug development process

TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

By Kim Ribbink • April 28, 2022

Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan

As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.

By Taren Grom • April 27, 2022

Laura Randa's aim to break down mental healthcare barriers for disabled patients

Despite the proliferation of mental health apps, many aren’t accessible for people with disabilities. The CEO of Toivoa plans to change that.

By Alexandra Pecci • April 27, 2022

Real-world data is making drug development more true to life

How RWD is moving from the background to the spotlight in pharma’s development process.

By Kelly Bilodeau • April 26, 2022

Mouse vs. machine: Using AI to solve the animal testing model in pharma

Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

By Michael Gibney • April 26, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022

From the fringes to the forefront — the mRNA era has taken hold of pharma

A look at what’s next for the industry’s buzziest technology.

By Kim Ribbink • April 22, 2022

The cannabis vanguard: A rare disease company looks to pioneer in the space

Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

By Jared Whitlock • April 21, 2022

A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

By Alexandra Pecci • April 21, 2022

Woman of the Week: Aura Biosciences' Dr. Elisabet de los Pinos

Dr. Elizabet de los Pinos, CEO and founder of Aura Biosciences, had a dream at a young age to change the course of cancer treatment and understand the underlying DNA of the disease.

By Taren Grom • April 20, 2022

For Global Blood Therapeutics, the connection to sickle cell disease runs deep

An underserved patient population is a guiding light for the company, which recently scored a new approval.

By Robin Robinson • April 19, 2022

A pharma mystery: Cancer-causing impurities drive joint search for answers

Pharmaceutical industry insiders and regulators are striving to overcome the ‘blind spots’ that contribute to nitrosamine contamination.

By Michael Gibney • April 19, 2022

With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

What now? Alzheimer's drugmakers ponder the path to approval

Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

By Kelly Bilodeau • April 14, 2022

Woman of the Week: iSpecimen's Jill Mullan

Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

By Taren Grom • April 13, 2022

Why the war in Ukraine could accelerate the deglobalization of clinical trials

COVID-19 slowed many studies — but the war could further strain clinical trials worldwide.

By Michael Gibney • April 12, 2022

'Bootcamp' helps rare disease advocates learn the ropes of drug development

Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

By Kim Ribbink • April 12, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

A planned trial revives a glimmer of hope for a Huntington's disease treatment

Roche brought a Huntington’s drug back to life after a jarring trial halt.

By Kelly Bilodeau • April 6, 2022

An analyst turned pharma CEO learns the art of operations

Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

By Jared Whitlock • April 5, 2022

Down but not out: How AVEO's CEO steered the company past an FDA rejection

Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

By Kim Ribbink • April 5, 2022

Clinical trial recruitment hits the local pharmacy counter

CVS Health's partnership with clinical trial software company Medable is designed to make recruitment easier for patients and drug makers alike.

By Kelly Bilodeau • April 5, 2022